Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in real-world practice in six European countries
Conclusion Despite the large proportion of patients receiving BTAs in this study, some patients with BMs are still not receiving early treatment to prevent SREs or to manage pain. Improving physicians’ understanding of the role of BTAs and the importance of early treatment following BM diagnosis has the potential to improve patient care. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - December 16, 2017 Category: Cancer & Oncology Source Type: research

Immune cells regulate VEGF signaling via release of VEGF and antagonistic soluble VEGF receptor ‐1
This article is protected by copyright. All rights reserved. (Source: Clinical and Experimental Immunology)
Source: Clinical and Experimental Immunology - December 13, 2017 Category: Allergy & Immunology Authors: Timm Hoeres, Martin Wilhelm, Manfred Smetak, Elisabeth Holzmann, Gundula Schulze ‐Tanzil, Josef Birkmann Tags: Original Article Source Type: research

Immune cells regulate VEGF signaling via release of VEGF and antagonistic soluble VEGF receptor-1.
This article is protected by copyright. All rights reserved. PMID: 29235095 [PubMed - as supplied by publisher] (Source: Clinical and Developmental Immunology)
Source: Clinical and Developmental Immunology - December 13, 2017 Category: Allergy & Immunology Authors: Hoeres T, Wilhelm M, Smetak M, Holzmann E, Schulze-Tanzil G, Birkmann J Tags: Clin Exp Immunol Source Type: research

Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update.
Abstract Purpose To update, in collaboration with Cancer Care Ontario (CCO), key recommendations of the American Society of Clinical Oncology (ASCO) guideline on the role of bone-modifying agents (BMAs) in metastatic breast cancer. This focused update addressed the new data on intervals between dosing and the role of BMAs in control of bone pain. Methods A joint ASCO-CCO Update Committee conducted targeted systematic literature reviews to identify relevant studies. Results The Update Committee reviewed three phase III noninferiority trials of dosing intervals, one systematic review and meta-analysis of studies of ...
Source: Clinical Genitourinary Cancer - December 9, 2017 Category: Cancer & Oncology Authors: Van Poznak C, Somerfield MR, Barlow WE, Biermann JS, Bosserman LD, Clemons MJ, Dhesy-Thind SK, Dillmon MS, Eisen A, Frank ES, Jagsi R, Jimenez R, Theriault RL, Vandenberg TA, Yee GC, Moy B Tags: J Clin Oncol Source Type: research

Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance).
Conclusion ZA every 3 months was more CE in reducing the risks of SRE than monthly denosumab. This analysis was one of the first to incorporate the costs of generic ZA and one of the first independent CE analyses not sponsored by either Novartis or Amgen, the makers of ZA and denosumab, respectively. ZA every 3 months is the more CE option and more reasonable alternative to monthly denosumab. PMID: 29023215 [PubMed - indexed for MEDLINE] (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - December 9, 2017 Category: Cancer & Oncology Authors: Shapiro CL, Moriarty JP, Dusetzina S, Himelstein AL, Foster JC, Grubbs SS, Novotny PJ, Borah BJ Tags: J Clin Oncol Source Type: research

Cost-Effectiveness of Treatments for the Management of Bone Metastases: A Systematic Literature Review
ConclusionsThe reviewed evidence suggests that bisphosphonate treatments are cost-effective options for bone metastases, while denosumab is unlikely to represent value for money. Evidence on EBR and Sr89 is limited and less conclusive. (Source: PharmacoEconomics)
Source: PharmacoEconomics - December 9, 2017 Category: Health Management Source Type: research

Protective effect of zoledronic acid on articular cartilage and subchondral bone of rabbits with experimental knee osteoarthritis.
In conclusion, ZOL increased the subchondral bone density, improved the microstructure and reduced the degeneration of articular cartilage in OA according to morphological as well as quantitative observation. ZOL exerted significant chondroprotective effects in a dose-dependent manner. A favorable chondroprotective effect was induced at the dose of 250 µg/kg. ZOL may represent a novel promising drug to complement the treatment of OA. PMID: 29201194 [PubMed] (Source: Experimental and Therapeutic Medicine)
Source: Experimental and Therapeutic Medicine - December 6, 2017 Category: General Medicine Tags: Exp Ther Med Source Type: research

Therapeutic Options to Improve Bone Health Outcomes in Duchenne Muscular Dystrophy: Zoledronic Acid and Pubertal Induction
(Source: Journal of Paediatrics and Child Health)
Source: Journal of Paediatrics and Child Health - December 4, 2017 Category: Pediatrics Authors: Angelina Lim, Margaret Zacharin, Janne Pitkin, Katy de Valle, Monique M Ryan, Peter J Simm Tags: Letter to the Editor Source Type: research

The Good and the Bad About the 2017 American College of Physicians Osteoporosis Guidelines.
Abstract PURPOSE: The American College of Physicians (ACP) published a set of guidelines on how to prevent fractures in men and women with low bone density or osteoporosis. As the population ages, the overall risk of fractures increases, thus burdening the health care system. These guidelines review current evidence for osteoporosis management, providing an update to the previous 2008 ACP's guidelines. METHODS: The ACP put forth 6 recommendations addressing the complexities in osteoporosis management based on evidence available through October 2016 with a focus on bisphosphonates, calcium, vitamin D, and estr...
Source: Clinical Therapeutics - November 28, 2017 Category: Drugs & Pharmacology Authors: Lagari V, Gavcovich T, Levis S Tags: Clin Ther Source Type: research

Novel Mutations in PLOD2 Cause Rare Bruck Syndrome
AbstractBruck syndrome is a rare autosomal recessive form of osteogenesis imperfecta (OI), which is mainly characterized by joint contractures and recurrent fragility fractures. Mutations inFKBP10 andPLOD2 were identified as the underlying genetic defects of Bruck syndrome. Here we investigated the phenotypes and the pathogenic mutations of three unrelated Chinese patients with Bruck syndrome. Clinical fractures, bone mineral density (BMD), bone turnover biomarkers, and skeletal images were evaluated in detail. The pathogenic mutations were identified by targeted next-generation sequencing and subsequently confirmed by San...
Source: Calcified Tissue International - November 24, 2017 Category: Orthopaedics Source Type: research

Hypophosphatemia, Severe Bone Pain, Gait Disturbance, and Fatigue Fractures After Iron Substitution in Inflammatory Bowel Disease: A Case Report
ABSTRACT Intravenous infusions of different iron formulations are recognized as a cause of hypophosphatemia. Chronic hypophosphatemia can alter bone metabolism and bone material structure. As a consequence, osteomalacia may develop and lead to bone fragility. Herein, we report a patient with Crohn's disease presenting with persistent hypophosphatemia and insufficiency fractures while receiving regular iron infusions due to chronic gastrointestinal bleeding. Previously, the patient regularly received vitamin D and also zoledronic acid. The patient underwent bone biopsy of the iliac crest that showed typical signs of osteoma...
Source: Journal of Bone and Mineral Research - November 21, 2017 Category: Orthopaedics Authors: Johann Bartko, Paul Roschger, Shahin Zandieh, Attila Brehm, Jochen Zwerina, Klaus Klaushofer Tags: Case Report Source Type: research

Updated Recommendations for the Diagnosis and Management of Osteoporosis: A Local Perspective
Postmenopausal osteoporosis and osteoporosis in elderly men are major health problems, with a significant medical and economic burden. Although osteopenia and osteoporosis are more common locally than in the West, fracture rates are generally less than in Western countries. Vitamin D deficiency is common in the region and contributes adversely to bone health. Vitamin D deficiency should be suspected and treated in all subjects with ostopenia or osteoporosis. The use of risk factors to determine fracture risk has been adopted by the World Health Organization and many international societies. Absolute fracture risk methodolo...
Source: Annals of Saudi Medicine - November 20, 2017 Category: General Medicine Tags: ISSUE 2 Source Type: research

In Vitro Study of the Effects of Denosumab on Giant Cell Tumor of Bone: Comparison with Zoledronic Acid.
Abstract Giant cell tumor of bone (GCTB) is a locally aggressive primary bone tumor that contains numerous osteoclasts formed from marrow-derived precursors through receptor activator of nuclear factor κ-B ligand (RANKL), an osteoclast differentiation factor expressed in neoplastic cells of GCTB. Denosumab, a fully human monoclonal antibody targeting RANKL, has recently been used for the treatment of GCTB, and superior treatment effects have been reported. The aim of this work was to elucidate the mechanism of action of denosumab, and the differences between denosumab and zoledronic acid at the level of GCTB...
Source: Pathology Oncology Research - November 20, 2017 Category: Pathology Authors: Shibuya I, Takami M, Miyamoto A, Karakawa A, Dezawa A, Nakamura S, Kamijo R Tags: Pathol Oncol Res Source Type: research

In  vivo effects of geranylgeraniol on the development of bisphosphonate-related osteonecrosis of the jaws
Bisphosphonate-related osteonecrosis of the jaws (BRONJ) is a complication of the bisphosphonate (BP) treatment and its pathopysiology is still not fully understood. The existing preventive and treatment options require updates and more attention. Geranylgeraniol (GGOH) so far demonstrated an increased activity and viability of the cells previously treated with zoledronic acid (ZA). The aim of this study was to evaluate the in  vivo effects of GGOH on the development of BRONJ. (Source: Journal of Cranio-Maxillofacial Surgery)
Source: Journal of Cranio-Maxillofacial Surgery - November 20, 2017 Category: ENT & OMF Authors: Filip Koneski, Danica Popovic-Monevska, Icko Gjorgoski, Jovanka Krajoska, Mirjana Popovska, Ilijana Muratovska, Boris Velickovski, Gordana Petrushevska, Vladimir Popovski Source Type: research

Topical zoledronic acid decreases micromotion induced bone resorption in a sheep arthroplasty model
Initial micromotion of a total hip replacement is associated with aseptic loosening. The use of bisphosphonates could be one way to reduce peri-implant bone resorption induced by micromotion. Bisphosphonates c... (Source: BMC Musculoskeletal Disorders)
Source: BMC Musculoskeletal Disorders - November 13, 2017 Category: Orthopaedics Authors: Thomas Jakobsen, S øren Kold, Juan Shiguetomi-Medina, Jorgen Baas, Kjeld Soballe and Ole Rahbek Tags: Research article Source Type: research

Kidney failure caused by tubular intersticial intersticial nephropathy with Fanconi syndrome after treatment with zoledronic acid.
Authors: Gutiérrez Sánchez MJ, Petkov Stoyanov V, Pedraza Cezón L, Martín Navarro JA PMID: 29122217 [PubMed - in process] (Source: Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia)
Source: Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia - November 12, 2017 Category: Urology & Nephrology Tags: Nefrologia Source Type: research

Acid sphingomyelinase inhibitors, imipramine and zoledronic acid, increase skeletal muscle tissue sensitivity to insulin action at old age.
Abstract Malfunction of skeletal muscles and dysregulated turnover of sphingolipids in the insulin responsive tissues have been determined at old age. Present article investigates the role of acid sphingomyelinase (SMase)-dependent ceramide accumulation in reduction of the skeletal muscle sensitivity to insulin action at old age. The 3-, 12- and 24-month-old Wistar male rats were used in the experiments. The progressive increase of ceramide content and ceramide/sphingomyeline (SM) ratio was determined in the extensor digitorum longus (EDL) muscle during aging of rats. The age-dependent ceramide accumulation was fo...
Source: General Physiology and Biophysics - November 10, 2017 Category: Physiology Authors: Hassouneh LKM, Timofiychuk OA, Babenko NA Tags: Gen Physiol Biophys Source Type: research

Effects on Bone Resorption Markers of Continuing Pamidronate or Switching to Zoledronic Acid in Patients with High Risk Bone Metastases from Breast Cancer
Conclusion Our analysis failed to find any association between serum BSAP, BSP, CTx or NTx levels and subsequent SRE risk in this cohort of patients. This lack of correlation between serum biomarkers and clinical outcomes could be due to influences of prior bisphosphonate treatment or presence of extra-osseous metastases in a significant proportion of enrolled patients. As such, caution should be used in biomarker interpretation and use to direct decision making regarding SRE risk for high risk patients in this setting. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - November 8, 2017 Category: Cancer & Oncology Source Type: research

Sequential Delivery of Doxorubicin and Zoledronic Acid to Breast Cancer Cells by CB[7]-Modified Iron Oxide Nanoparticles
ACS Applied Materials& InterfacesDOI: 10.1021/acsami.7b11423 (Source: ACS Applied Materials and Interfaces)
Source: ACS Applied Materials and Interfaces - November 7, 2017 Category: Materials Science Authors: Farah Benyettou, Marwa Alhashimi, Matthew O ’Connor, Renu Pasricha, Jeremy Brandel, Hassan Traboulsi, Javed Mazher, John-Carl Olsen and Ali Trabolsi Source Type: research

Sensitive and Rapid RPHPLC Quantification of Zoledronic Acid in a Hydroxyapatitebased Nanoparticles
D. K. Khajuria* and Rema Razdan (Source: Indian Journal of Pharmaceutical Sciences)
Source: Indian Journal of Pharmaceutical Sciences - November 7, 2017 Category: Drugs & Pharmacology Source Type: research

Effect of zoledronic acid therapy on postmenopausal osteoporosis between the Uighur and Han population in Xinjiang: An open ‐label, long‐term safety and efficacy study
This study aimed to investigate zoledronic acid treatment on postmenopausal osteoporosis in Uighur and Han patients in Xinjiang province, China. MethodsA self‐controlled and prospective trial design was adopted. A total of 155 Uighur and 151 Han patients were enrolled. All subjects received an intravenous infusion of zoledronic acid (5 mg) at day 0 (baseline) and at 12 months. Patients were followed up for 24 months; the bone mineral density (BMD) of the left total hip and L1–L4 vertebrae was measured at day 0 and at 24 months. Results and discussionBMD was significantly higher after zoledronic ...
Source: Journal of Clinical Pharmacy and Therapeutics - November 7, 2017 Category: Drugs & Pharmacology Authors: W. Xu, C. Xiang, H. Wang, H. Yuan, X. Zhao, X. Xiao Tags: ORIGINAL ARTICLE Source Type: research

Effect of zoledronic acid therapy on postmenopausal osteoporosis between the Uighur and Han population in Xinjiang: An open ‐label, long‐term safety and efficacy study
Journal of Clinical Pharmacy and Therapeutics, EarlyView. (Source: Journal of Clinical Pharmacy and Therapeutics)
Source: Journal of Clinical Pharmacy and Therapeutics - November 7, 2017 Category: Drugs & Pharmacology Source Type: research

Effect of zoledronic acid therapy on postmenopausal osteoporosis between the Uighur and Han population in Xinjiang: An open ‐label, long‐term safety and efficacy study
Journal of Clinical Pharmacy and Therapeutics,Volume 43, Issue 3, Page 336-341, June 2018. (Source: Journal of Clinical Pharmacy and Therapeutics)
Source: Journal of Clinical Pharmacy and Therapeutics - November 7, 2017 Category: Drugs & Pharmacology Authors: W. Xu MD, PhD , C. Xiang MD , H. Wang MD , H. Yuan MD , X. Zhao MD , X. Xiao MD, PhD Source Type: research

Longitudinal Effects of Teriparatide or Zoledronic Acid on Bone Modeling ‐ and Remodeling‐based Formation in the SHOTZ Study
Abstract Previously we reported on bone histomorphometry, biochemical markers, and bone mineral density distribution following 6 and 24 months of treatment with teriparatide (TPTD) or zoledronic acid (ZOL) in the SHOTZ study. The study included a 12‐month primary study period, with treatment (TPTD 20 μg/day by subcutaneous injection or ZOL 5 mg/year by intravenous infusion) randomized and double‐blind until the month 6 biopsy (TPTD n=28, ZOL n=30 evaluable), then open‐label, with an optional 12‐month extension receiving the original treatment. A second biopsy (TPTD, n=10; ZOL, n=9) was collected from the contral...
Source: Journal of Bone and Mineral Research - November 1, 2017 Category: Orthopaedics Authors: David W. Dempster, Hua Zhou, Valerie A. Ruff, Thomas E. Melby, Jahangir Alam, Kathleen A. Taylor Tags: Original Article Source Type: research

Preventive dental management of osteonecrosis of the jaws related to zoledronic acid treatment
ConclusionsBRONJ occurred significantly in patients who underwent dental extractions after the initiation of ZA and did not accomplish a preventive dental program.This article is protected by copyright. All rights reserved. (Source: Oral Diseases)
Source: Oral Diseases - November 1, 2017 Category: ENT & OMF Authors: J A Coello ‐Suanzes, V Rollon‐Ugalde, A Castaño‐Seiquer, E Lledo‐Villar, J Herce‐Lopez, P Infante‐Cossio, A Rollon‐Mayordomo Tags: Original Article Source Type: research

Zoledronic Acid, Bevacizumab and Dexamethasone-Induced Apoptosis, Mitochondrial Oxidative Stress, and Calcium Signaling Are Decreased in Human Osteoblast-Like Cell Line by Selenium Treatment.
In conclusion, we observed that Zol, Bev, and Dex-induced apoptosis, mitochondrial oxidative stress, and calcium signaling are decreased in human osteoblast-like cell line by the Se treatment. Our findings may be relevant to the etiology and treatment of Zol, Bev, and Dex-induced osteonecrosis by Se. PMID: 29081061 [PubMed - as supplied by publisher] (Source: Biological Trace Element Research)
Source: Biological Trace Element Research - October 28, 2017 Category: Biology Authors: Yazıcı T, Koçer G, Nazıroğlu M, Övey İS, Öz A Tags: Biol Trace Elem Res Source Type: research

Significant Improvement of Clinical Symptoms, Bone Lesions, and Bone Turnover after Long-Term Zoledronic Acid Treatment in Patients with a Severe Form of Camurati-Engelmann Disease
Camurati-Engelmann disease (CED) is an ultrarare autosomal dominant bone dysplasia. Cortical thickening of the diaphyses of the long bones with narrowing of the medullary cavity are associated with bone pain, waddling gait, muscular weakness, easy fatigability, and a marfanoid body habitus. There is no specific treatment for CED. Nonsteroidal anti-inflammatory drugs or glucocorticoids are ineffective in improving bone lesions. A family with a mild to severe form of CED is described. Two patients received long-term bisphosphonate treatment: the 19-year-old female proband was treated with zoledronic acid for 2.2 years; the 4...
Source: Molecular Syndromology - October 25, 2017 Category: Molecular Biology Source Type: research

Therapeutic approaches for protecting bone health in patients with breast cancer.
GG Abstract Improvements in the survival of patients with breast cancer, together with a better understanding of the pathology of the disease, have led to the emergence of bone health as a key aspect of patient management. Patients with breast cancer are typically at risk of skeletal complications throughout their disease course. The receptor activator of nuclear factor κ B ligand (RANKL) inhibitor denosumab and bisphosphonates (e.g. zoledronic acid) are approved in Europe for the prevention of skeletal-related events (pathologic fracture, radiation or surgery to bone, and spinal cord compression) in adults...
Source: Breast - October 23, 2017 Category: Cancer & Oncology Authors: Lüftner D, Niepel D, Steger GG Tags: Breast Source Type: research

Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) in an osteoporotic patient chronically treated with bisphosphonates
Case report: A.C., female of Italian descent, age 87years, consulted in February 2013. She had a history of osteoporosis and had taken alendronate weekly for several years. She did not have densitometric studies. Due to low back pain an orthopedist had indicated i.v. zoledronic acid, 5mg/year for 3years (2006 –2008). She was on simvastatin, carvedilol, enalapril, with occasional supplements of ergocalciferol. In 2009 she suffered a fall and sustained a subtrochanteric fracture of the left femur. She was operated on and recovered uneventfully. (Source: Bone)
Source: Bone - October 18, 2017 Category: Orthopaedics Authors: A. S ánchez, G. Bruchmann, R. Blanco Tags: C ódigo: 4 Source Type: research

The effect of once-yearly zoledronic acid on hip structural and biomechanical properties derived using computed tomography (CT) in Japanese women with osteoporosis
The effects of zoledronic acid on hip structural and biomechanical properties were evaluated in Japanese patients with osteoporosis by computed tomography (CT).The subjects included in this study were a subset of female subjects (zoledronic acid group, 49 subjects; placebo group, 53 subjects) in the phase 3 trial (ZONE study) who were available for multi-detector row CT (MDCT) scanning. Eligible subjects were those diagnosed with primary osteoporosis based on the Diagnostic Criteria for Primary Osteoporosis (2000) by the Japanese Society for Bone and Mineral Research and who had between one and four fractured vertebrae loc...
Source: Bone - October 13, 2017 Category: Orthopaedics Authors: Masako Ito, Teruki Sone, Masataka Shiraki, Satoshi Tanaka, Chika Irie, Yuri Ota, Toshitaka Nakamura Source Type: research

[Comment] Adjuvant zoledronic acid to treat breast cancer: not for all
Bisphosphonates have been extensively studied in the adjuvant setting as a host-directed therapy to reduce the risk of breast-cancer relapse. The Early Breast Cancer Trialists' Collaborative Group (EBCTCG) patient-level meta-analysis of adjuvant bisphosphonates, which included 18  776 women with breast cancer, showed a reduction in breast-cancer-associated death among postmenopausal women (hazard ratio [HR] 0·82, 95% CI 0·73–0·93). This outcome was mainly due to the reduction in bone recurrence. Thus, several guidelines have included zoledronic acid and clodronic acid as adjuvant treatments for...
Source: The Lancet Oncology - October 13, 2017 Category: Cancer & Oncology Authors: Lu ís Costa, Arlindo R Ferreira Tags: Comment Source Type: research

[Articles] Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial
MAF status can predict likelihood of benefit from adjuvant zoledronic acid and merits further investigation as a potential companion diagnostic. (Source: The Lancet Oncology)
Source: The Lancet Oncology - October 13, 2017 Category: Cancer & Oncology Authors: Robert Coleman, Andrew Hall, Joan Albanell, Andrew Hanby, Richard Bell, David Cameron, David Dodwell, Helen Marshall, Jo ël Jean-Mairet, Juan-Carlos Tercero, Federico Rojo, Walter Gregory, Roger R Gomis Tags: Articles Source Type: research

Interventions for managing medication-related osteonecrosis of the jaw.
CONCLUSIONS: Prophylaxis of MRONJOne open-label RCT provided some evidence that dental examinations in three-month intervals and preventive treatments may be more effective than standard care for reducing the incidence of MRONJ in individuals taking intravenous bisphosphonates for advanced cancer. We assessed the certainty of the evidence to be low.There is insufficient evidence to either claim or refute a benefit of either of the interventions tested for prophylaxis of MRONJ (i.e. PRGF inserted into the postextraction alveolus during dental extractions, and wound closure by primary or secondary intention after dental extr...
Source: Cochrane Database of Systematic Reviews - October 6, 2017 Category: General Medicine Authors: Beth-Tasdogan NH, Mayer B, Hussein H, Zolk O Tags: Cochrane Database Syst Rev Source Type: research

The skeletal-related events of denosumab versus zoledronic acid in patients with bone metastases: A meta-analysis of randomized controlled trials
Conclusion Denosumab was more effective than ZA in reducing the incidence of SRE in patients with bone metastases. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - October 4, 2017 Category: Cancer & Oncology Source Type: research

Improved union and bone strength in a mouse model of NF1 pseudarthrosis treated with recombinant human bone morphogenetic protein ‐2 and zoledronic acid
Journal of Orthopaedic Research, EarlyView. (Source: Journal of Orthopaedic Research)
Source: Journal of Orthopaedic Research - October 4, 2017 Category: Orthopaedics Source Type: research

Comparison of the Effects of Local and Systemic Zoledronic Acid Application on Mandibular Distraction Osteogenesis
Abstract: Bisphosphonates are antibone resorptive drugs that are used to prevent bone tissue resorption in several skeletal diseases. The aim of this study was to examine the effects of systemic and local applications of zoledronic acid (ZA) on newly regenerated bone in a model of experimental distraction osteogenesis (DO). To do this mandibular DO was applied to 30 adult female Sprague Dawley rats, which were randomly divided into 3 groups: control, DO only, systemic zoledronic acid (SZA), and local zoledronic acid (LZA). In the LZA group, the gap between the bone fragments was filled with a gelatin sponge soaked in 2 m...
Source: Journal of Craniofacial Surgery - October 1, 2017 Category: Surgery Tags: Brief Clinical Studies Source Type: research

Abaloparatide For Risk Reduction of Nonvertebral And Vertebral Fractures In Postmenopausal Women With Osteoporosis: A Network Meta-Analysis
To assess the relative efficacy of abaloparatide compared with osteoporosis treatment options (alendronate, denosumab, ibandronate, raloxifene, risedronate, romosozumab, strontium ranelate, teriparatide, zoledronic acid). (Source: Value in Health)
Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: J Reginster, F Bianic, R Campbell, M Martin, S Williams, L Fitzpatrick Source Type: research

Estimation of The Health Benefit Associated With A Potential Denosumab-Induced Extension of Progression Free Survival In Multiple Myeloma Patients
The objective of this study was to quantify the potential incremental health benefit associated with a Denosumab-induced extension of PFS, in MM patients. (Source: Value in Health)
Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: L Sabatelli, A Jamotte, C Giannopoulou Source Type: research

Hypophosphatemia, severe bone pain, gait disturbance and fatigue fractures after iron substitution in inflammatory bowel disease: a case report
This article is protected by copyright. All rights reserved (Source: Journal of Bone and Mineral Research)
Source: Journal of Bone and Mineral Research - October 1, 2017 Category: Orthopaedics Authors: J. Bartko, P. Roschger, S. Zandieh, A. Brehm, J. Zwerina, K. Klaushofer Tags: Case Report Source Type: research

Role of Osteogenic Coatings on Implant Surfaces in Promoting Bone-To-Implant Contact in Experimental Osteoporosis: A Systematic Review and Meta-Analysis
Conclusion: Although experimental studies have shown that osteogenic coatings are effective in enhancing BIC, their clinical relevance requires further investigations. (Source: Implant Dentistry)
Source: Implant Dentistry - September 27, 2017 Category: Dentistry Tags: Meta-Analyses and Systematic Reviews Source Type: research

Multicenter Study on Observation of Acute ‐phase Responses After Infusion of Zoledronic Acid 5 mg in Chinese Women with Postmenopausal Osteoporosis
ConclusionsCompared with Western populations, Chinese patients had a higher rate of fever and pain after their first zoledronic acid infusion. These symptoms were often mild to moderate in intensity and transient in duration. NSAID could effectively reduce the incidence and severity of such APR. (Source: Orthopaedic Surgery)
Source: Orthopaedic Surgery - September 27, 2017 Category: Orthopaedics Authors: Yue Ding, Jian ‐Cheng Zeng, Fei Yin, Chun‐lin Zhang, Yan Zhang, Shi‐xun Li, Xun Liu, Chao Zhang, Qing‐yun Xue, Hua Lin, Fu‐xing Pei Tags: CLINICAL ARTICLE Source Type: research

Zoledronic acid augments the radiosensitivity of cancer cells through perturbing S- and M-phase cyclins and p21(CIP1) expression.
Authors: Du C, Wang Y, Li H, Huang Y, Jiang O, You Y, Luo F Abstract Radiotherapy and adjuvant chemotherapy have become the standard treatments for multiple types of cancer. Although cancer cells are usually sensitive to radiotherapy, metastasis and local failure still occur mainly due to developed resistance to radiotherapy. Thus, it is critical to improve therapeutics for cancer treatment. The present study demonstrated that third-generation bisphosphonate zoledronic acid (ZOL), even at a low concentration, augments the radiosensitivity of cancer cells exposed to ionizing radiation (IR) by inducing S-phase arrest...
Source: Oncology Letters - September 26, 2017 Category: Cancer & Oncology Tags: Oncol Lett Source Type: research

Zoledronic acid inhibits infiltration of tumor-associated macrophages and angiogenesis following transcatheter arterial chemoembolization in rat hepatocellular carcinoma models.
In conclusion, ZA treatment enhanced the effects of TACE through inhibiting TAM infiltration and tumor angiogenesis in rat HCC models. PMID: 28943915 [PubMed] (Source: Oncology Letters)
Source: Oncology Letters - September 26, 2017 Category: Cancer & Oncology Tags: Oncol Lett Source Type: research

A new mathematical approach to predict the actual drug release from hydrogels.
Abstract In the present study, we have developed a mathematical model of drug release from a film of highly swellable gelatin based hydrogel mixed with graphene. The model considers the hydrogel volume expansion because of the swelling as well as the non-linear concentration dependence of the diffusion coefficients for the solvent and the drug. An additionl term is considered for the drug diffusion coefficient enabling the model to predict the drug maximum release from the hydrogel. The model parameters are estimated by genetic algorithem and the model resutls are validated using data sets obtained from experiment...
Source: European Journal of Pharmaceutical Sciences - September 26, 2017 Category: Drugs & Pharmacology Authors: Zeinali K AH, Vahidi O, Naghib SM Tags: Eur J Pharm Sci Source Type: research

Metastatic Hepatocellular Carcinoma Treated With Zoledronic Acid.
PMID: 28945506 [PubMed - as supplied by publisher] (Source: JOP)
Source: JOP - September 25, 2017 Category: Gastroenterology Authors: Nguyen AL, Cao H, Thinn MM Tags: J Oncol Pract Source Type: research

Systematic Review and Network Meta ‐Analysis on the Relative Efficacy of Osteoporotic Medications: Men with Prostate Cancer on Continuous Androgen Deprivation Therapy to Reduce Risk of Fragility Fractures
Abstract BackgroundAndrogen deprivation therapy (ADT) is an effective treatment for men with advanced prostate cancer, but loss of bone mineral density (BMD) is a major risk factor for fractures. This analysis evaluated the relative effectiveness of osteoporosis treatments using BMD as a surrogate endpoint for fragility fractures in men on continuous ADT. MethodWe included randomized controlled trials studying bisphosphonates, denosumab, toremifene, and raloxifene in patients with non‐metastatic prostate cancer on ADT for review. Primary outcomes included percentage change in BMD from baseline at total hip, lumbar spine ...
Source: BJU International - September 18, 2017 Category: Urology & Nephrology Authors: Yeesha Poon, Petros Pechlivanoglou, Shabbir M H Alibhai, David Naimark, Jeffrey S Hoch, Emmanuel Papadimitropoulos, Mary ‐Ellen Hogan, Murray Krahn Tags: Review Source Type: research

Safety and efficacy of hydroxyapatite scaffold in the prevention of jaw osteonecrosis in vivo
Abstract Two scaffolds of chitosan/sodium alginate/hydroxyapatite (Ch/NaAlg/Hap) 1:1:0.2 and 1:1:0.6 were evaluated in the prevention of bisphosphonate‐induced jaw osteonecrosis. Two groups of rats (n = 24, according to the euthanasia time: 15 or 30 days after the last Zoledronic acid (ZA) administration) were subdivided in four subgroups (n = 6): I – Control (saline + teeth extraction); II – ZA 0.6 mg/kg + teeth extraction; III – ZA + teeth extraction + scaffold 1:1:0.2; IV – ZA + teeth extraction&th...
Source: Journal of Biomedical Materials Research Part B: Applied Biomaterials - September 13, 2017 Category: Materials Science Authors: Adriana Duarte de Almeida, Fernanda Gomes Leite, Marco Vin ícius Chaud, Márcia de Araújo Rebelo, Liliane Cristine Ferreira de Souza Borges, Fabia Judice Marques Viroel, Alessandre Hataka, Denise Grotto Tags: Original Research Report Source Type: research

A Case of Metastatic Collecting Duct Carcinoma Whose Massive Skull Bone Metastasis was Prominently Reossified by Gemcitabine Plus Cisplatin Chemotherapy Combined with Zoledronic Acid
Publication date: November 2017 Source:Urology Case Reports, Volume 15 Author(s): Makoto Kawaguchi, Keiichi Ito, Hideyuki Shimazaki, Tomohiko Asano The present case underwent right laparoscopic radical nephrectomy for collecting duct carcinoma (CDC). Recurrence occurred in the lung and the bone (skull and lumber vertebra) in 2011. Gemcitabine plus cisplatin (GC) chemotherapy and monthly zoledronic acid (ZA) was then started. The massive skull bone metastases were prominently reossified after several courses of the therapy. The patient received 16 courses of GC chemotherapy and monthly ZA, and pulmonary metastases and reos...
Source: Urology Case Reports - September 9, 2017 Category: Urology & Nephrology Source Type: research

Significant Improvement of Clinical Symptoms, Bone Lesions, and Bone Turnover after Long-Term Zoledronic Acid Treatment in Patients with a Severe Form of Camurati-Engelmann Disease
Camurati-Engelmann disease (CED) is an ultrarare autosomal dominant bone dysplasia. Cortical thickening of the diaphyses of the long bones with narrowing of the medullary cavity are associated with bone pain, waddling gait, muscular weakness, easy fatigability, and a marfanoid body habitus. There is no specific treatment for CED. Nonsteroidal anti-inflammatory drugs or glucocorticoids are ineffective in improving bone lesions. A family with a mild to severe form of CED is described. Two patients received long-term bisphosphonate treatment: the 19-year-old female proband was treated with zoledronic acid for 2.2 years; the 4...
Source: Molecular Syndromology - September 8, 2017 Category: Molecular Biology Source Type: research

Bone structural characteristics and response to bisphosphonate treatment in children with Hajdu-Cheney Syndrome.
Conclusions: Increased bone resorption and low cortical thickness are consistent with the effect of activating NOTCH2 mutations, which stimulate osteoclastogenesis. The increase in lumbar spine bone density and radial cortical thickness and density by BP therapy provides evidence of beneficial treatment effects in children with HJCYS. PMID: 28938420 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - September 8, 2017 Category: Endocrinology Authors: Sakka S, Gafni RI, Davies JH, Clarke B, Tebben P, Samuels M, Saraff V, Klaushofer K, Fratzl-Zelman N, Roschger P, Rauch F, Högler W Tags: J Clin Endocrinol Metab Source Type: research